Joseph Spare
Psychiatry · Marion, OHNPI 1548238298
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 51.6% of the total. Reporting peaked in 2019 at $8,452 and has fallen 73.7% since, to $2,227 in 2025. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 885 payments — averaging $30.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$14K
- AbbVie$3K
- Johnson & Johnson$1K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$987
- Lundbeck LLC$963
- plus $6K from 24 others
What the payments were for
- Consulting fees$4,31316%
- Speaking & faculty fees$9,54036%
- Travel & lodging$1030%
- Food & beverage$12,43047%
- Education$1661%
- Gifts$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 87 | $13,711 |
| AbbVie(2 entities) | 146 | $2,763 |
| Johnson & Johnson | 83 | $1,249 |
| Alkermes, Inc. | 76 | $1,053 |
| Neurocrine Biosciences, Inc. | 48 | $987 |
| Lundbeck LLC | 69 | $963 |
| Otsuka America Pharmaceutical, Inc. | 67 | $878 |
| Indivior Inc. | 56 | $863 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $793 |
| Vanda Pharmaceuticals Inc. | 29 | $682 |
| Sunovion Pharmaceuticals Inc. | 60 | $633 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $442 |
| Axsome Therapeutics, Inc. | 15 | $318 |
| Avanir Pharmaceuticals, Inc. | 11 | $250 |
| Supernus Pharmaceuticals, Inc. | 8 | $145 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| Noven Therapeutics, LLC | 7 | $96 |
| Tris Pharma Inc | 5 | $96 |
| Acadia Pharmaceuticals Inc | 7 | $93 |
| Merck | 6 | $79 |
| Harmony Biosciences LLC | 3 | $68 |
| Corium, LLC | 3 | $60 |
| Ironshore Pharmaceuticals Inc. | 4 | $57 |
| Eisai Inc. | 3 | $49 |
| Braeburn Inc. | 3 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Orexo US, Inc. | 2 | $26 |
| Shire North American Group Inc | 1 | $12 |
| Neuronetics, Inc. | 1 | $10 |
| Validus Pharmaceuticals LLC | 2 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,554 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 72 | $187,375 |
| VraylarCariprazine Hcl | 115 | $145,166 |
| Risperdal ConstaRisperidone Microspheres | 68 | $129,298 |
| AristadaAripiprazole Lauroxil | 34 | $102,223 |
| CaplytaLumateperone Tosylate | 49 | $57,928 |
| RexultiBrexpiprazole | 34 | $46,862 |
| PerserisRisperidone | 17 | $43,467 |
| Lurasidone Hcl | 78 | $36,780 |
| Clozapine | 360 | $33,942 |
| Abilify MaintenaAripiprazole | 12 | $31,082 |
| TrintellixVortioxetine Hydrobromide | 56 | $27,535 |
| Aripiprazole | 296 | $18,554 |
| FetzimaLevomilnacipran Hcl | 13 | $14,349 |
| SpravatoEsketamine Hcl | 13 | $14,162 |
| BelsomraSuvorexant | 29 | $12,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Spravato | $1,249 | $330,835153 claims |
| AbbVieVraylar, Fetzima | $2,763 | $159,514128 claims |
| Alkermes, Inc.Aristada | $1,053 | $102,22334 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $878 | $77,94446 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $793 | $57,92849 claims |
| Indivior Inc.Perseris | $863 | $43,46717 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $442 | $40,03579 claims |
| MerckBelsomra | $79 | $12,86129 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $250 | $6,96411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Marion
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
- Tracey SkaleCincinnati$674K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.